Furthermore, the expression of AKT and NEMO proteins was decreased in those ATL cells in a dose-dependent manner (Figure 6C,D), thus indicating that PRMT5/MEP50 inhibition can be a promising therapeutic target for cancer vulnerability in NDRG2low ATL cells. The gene discussed is AKT1; the disease is cancer.